• EADV 2024 Congress: New perspectives on melanoma

    Recent advances in melanoma diagnosis and treatment emphasise the importance of new biomarkers for early detection and innovative therapies for advanced melanoma.

  • Tamuzimod delivers promising long-term data in ulcerative colitis

    Tamuzimod improved clinical, endoscopic, and histologic outcomes compared with placebo in moderately to severely active UC at week 52.

  • Upadacitinib associated with normalisation of HRQoL in UC

    Upadacitinib induction and maintenance therapy were associated with higher rates of normalisation of health-related quality-of-life (HRQoL) than placebo.

  • TL1A inhibitor tulisokibart shows potential in ulcerative colitis

    Tulisokibart displayed durable improvements in clinical and endoscopic outcomes in patients with moderately to severely active ulcerative colitis.

  • New insights into perianal fistulising CD pathogenesis may lead to new therapeutics

    Perianal fistulising Crohn’s disease was associated with increased IFN-γ expression and response in fistula tracts and luminal mucosa.

  • Exploring zibotentan plus dapagliflozin for cirrhosis

    Data from the cirrhosis subpopulation in the ZENITH-CKD trial suggest that the zibotentan and dapagliflozin combination may benefit liver health.

  • Cendakimab meets primary endpoints in eosinophilic oesophagitis

    Cendakimab outperformed placebo in patients with eosinophilic oesophagitis (EoE) across various efficacy endpoints in a phase 3 study.

  • Tradipitant improves symptoms of motion sickness

    Tradipitant successfully reduced nausea and vomiting associated with motion sickness in a clinical trial. Both low dose and high doses were well-tolerated.

  • Diagnostic accuracy of fluorescence confocal laser microscopy after EUS-TA

    Fluorescence confocal laser microscopy may allow real-time tissue diagnosis from solid pancreatic lesions, via an endoscopic ultrasound procedure.

  • Guar gum alleviates IBS-related constipation in randomised-controlled trial

    Partially hydrolysed guar gum (PHGG) appeared to be efficacious in patients with irritable bowel syndrome-associated chronic constipation.

  • Medical Case: A fever of unknown origin

    A 66-year-old patient enters the ER with persistent fever, night sweats and significant weight loss. He is admitted with the diagnosis of “persistent bronchopneumonia”...

  • An accelerated treatment approach may save lives in pancreatic walled-off necrosis

    An accelerated treatment algorithm appeared to benefit patients with large pancreatic WON in terms of length-of-stay in the hospital and major complications.

  • Is FMT a viable option to treat primary C. difficile infections?

    A study found faecal microbiota transplantation was safe and non-inferior to vancomycin in patients with primary Clostridioides difficile infections.

  • CULTIVATE: Good signal for etrasimod in Crohn’s disease

    Etrasimod was associated with favourable outcomes and tolerability in patients with moderately to severely active CD in a phase 2 trial extension.

  • Malabsorption - key concepts and clinical approaches

    Key issues were discussed at the UEG Week related to current approaches to diagnostics, treatment and practical takeaways of malabsorption syndromes.

  • Mistakes in Lower GI: insights from UEG Week 2024

    A special congres session took a critical look at common errors in the management of lower gastrointestinal conditions, providing insights for clinical practice.

  • From guidelines to clinical practice: HPB

    Hepatobiliary and disease guidelines and updates were discussed during a session on prancreas-related cancer, exocrine insufficiency, cysts, and NASH.

  • Familial hidradenitis suppurativa associated with higher metabolic diseases risk

    A meta-analysis showed that HS familial cases are associated with higher cardiovascular diseases, hyperlipidaemia, and diabetes mellitus risk.

  • Deuruxolitinib significantly improves hair satisfaction in alopecia areata

    Post-hoc analysis of the THRIVE-AA1 and THRIVE-AA2 trials showed satisfaction in the THRIVE-AA1 and THRIVE-AA2 trials as early as week 12.

  • JAK1 inhibitor shows promising long-term efficacy in PN

    Povorcitinib led to a sustained reduction of pruritus and skin lesions in prurigo nodularis in a randomised-controlled phase 2 study.

  • 1 |
  • 2 |
  • 3 |
  • 4 |
  • 5 |
  • 6 |
  • 7 |
  • 8 |
  • 9 |
  • 10 |